Drug Profile
Donepezil/memantine extended release - Adamas Pharmaceuticals
Alternative Names: ADS-8703; ADS-8704; Arimenda; donepezil HCl/memantine ER; donepezil HCl/Namenda XR®; MDX-8704; memantine ER/donepezil HCl; memantine ER/donepezil IR; Memantine/donepezil; Namenda; Namenda XR®/donepezil HCl; NamzaricLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Adamas Pharmaceuticals
- Developer AbbVie; Adamas Pharmaceuticals
- Class Analgesics; Antidementias; Antiparkinsonians; Antispastics; Indans; Nootropics; Organic bridged compounds; Piperidines; Small molecules
- Mechanism of Action Acetylcholinesterase inhibitors; NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Alzheimer's disease
- No development reported Dementia
Most Recent Events
- 24 Nov 2021 Adamas Pharmaceuticals has been acquired by Supernus Pharmaceuticals
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 31 Jan 2019 Chemical structure information added